ORIC Pharmaceuticals Conference Call Summary Company Overview - **Company**: ORIC Pharmaceuticals (NasdaqGS:ORIC) - **Focus**: Development of rinzimetostat, a PRC2 inhibitor for prostate cancer, and enozertinib, an EGFR inhibitor for non-small cell lung cancer, in collaboration with Bayer and Johnson & Johnson [4][6] Key Points and Arguments Clinical Data and Pipeline - **Rinzimetostat**: A next-generation PRC2 inhibitor designed for superior potency and a 20-hour clinical half-life, minimizing toxicity [5] - **Phase III Trial**: The first phase III trial, named Himalayas-1, will target post-abiraterone metastatic CRPC, a market worth $3.5 billion annually in the U.S. [6][10] - **Efficacy**: Rinzimetostat shows competitive efficacy with early landmark radiographic progression-free survival (RPFS) rates and a favorable safety profile compared to existing therapies [5][8][10] Competitive Landscape - **Current Therapies**: Existing treatments like enzalutamide and docetaxel show median RPFS of 6-9 months, while rinzimetostat aims for a double-digit RPFS [6][7] - **Comparison with Meverometostat**: Rinzimetostat's early data suggests it may outperform meverometostat in terms of safety and efficacy, with a cleaner safety profile [7][9][36] Safety Profile - **Adverse Events**: Most adverse events for rinzimetostat in combination with darolutamide are grade 1 or 2, with a significantly lower incidence of severe events compared to competitors [9][25][36] - **Patient Population**: The trial population is more heavily pretreated than competitors, with a median baseline PSA of 26 for the 400 mg dose group, indicating a more advanced disease state [24][72] Market Potential - **Addressable Market**: The U.S. market for post-abiraterone mCRPC is estimated at over $3.5 billion, with potential expansion into other prostate cancer indications, increasing the total market to over $10 billion [10][41] - **Physician Insights**: Market research indicates a strong preference for rinzimetostat due to its safety profile, potentially capturing 80% of the PRC2 class market share [49] Future Development - **Additional Trials**: Plans for future phase III trials in other indications, including metastatic castration-sensitive prostate cancer and colorectal cancer, are underway [42][50] - **FDA Engagement**: Regular communication with the FDA is ongoing, with an end-of-phase I meeting planned to finalize the trial design and RP3D selection [65][66] Other Important Content - **Preclinical Data**: Rinzimetostat has shown superior potency in preclinical studies compared to first-generation PRC2 inhibitors, supporting its potential as a best-in-class therapy [11][12] - **Mechanistic Rationale**: The drug's ability to reverse epigenetic reprogramming in prostate cancer cells enhances its therapeutic potential when combined with AR inhibitors [14][15] This summary encapsulates the critical insights from the ORIC Pharmaceuticals conference call, highlighting the company's strategic focus on rinzimetostat and its promising clinical data, competitive positioning, and market potential.

Summary of ORIC Pharmaceuticals FY Conference Call Company Overview - **Company Name**: ORIC Pharmaceuticals (NasdaqGS:ORIC) - **Industry**: Oncology - **Mission**: Overcoming Resistance in Cancer, focusing on developing therapies for cancer patients [2][3] Key Pipeline Assets - **Rinsey-Metastat**: A PRC2 inhibitor for prostate cancer, expected to have a phase three data readout in the second half of 2027 [3][11] - **Enosertinib**: A brain-penetrant TKI for lung cancer, targeting EGFR exon 20 and PAC mutations, with a phase three dose selected [5][35] Financial Position - **Cash Runway**: Well-funded with cash runway extending into the second half of 2028, allowing for continued development of both pipeline assets [3][11] Clinical Development Highlights Rinsey-Metastat - **Combination Studies**: Being developed in combination with apalutamide (J&J) and daralutamide (Bayer) [4][7] - **Safety Profile**: Demonstrated a differentiated safety profile compared to competitors, which is crucial for long-term dosing [8][29] - **Efficacy Data**: - Confirmed PSA response rates of 40% for PSA 50 and 20% for PSA 90, significantly higher than expected rates for AR inhibitors alone [24] - ctDNA clearance rate of 59%, indicating strong activity [26][27] Enosertinib - **CNS Activity**: Achieved a 100% intracranial objective response rate (ORR) in patients with measurable disease, highlighting its potential in treating CNS metastases [10][33] - **Patient Enrollment**: Allowed patients with active untreated CNS metastases, which is uncommon in competitor studies [34] Competitive Landscape - **Main Competitor**: Pfizer's mevrometostat, which has shown promising results but comes with higher toxicity [6][28] - **Market Opportunity**: The prostate cancer market is substantial, with AR inhibitors generating $11 billion in global revenue [16][17] Future Milestones - **Phase 3 Studies**: Expected to initiate one or two phase 3 studies within the year for both Rinsey-Metastat and Enosertinib [46] - **Data Releases**: Anticipated data from dose optimization studies in Q1 2026, focusing on efficacy and safety [50] Additional Insights - **Long-term Durability**: The combination of Rinsey-Metastat with AR inhibitors aims to extend the durability of treatment, addressing a significant unmet need in prostate cancer [17][19] - **Broader Applications**: Potential future development of PRC2 inhibitors in other cancers, including lung and breast cancer [30] Conclusion - ORIC Pharmaceuticals is positioned to make significant advancements in oncology with its innovative pipeline, particularly in addressing unmet needs in prostate and lung cancer, while maintaining a strong financial position to support its development efforts [46]

Summary of Oric Pharmaceuticals (ORIC) Update / Briefing May 28, 2025 Company Overview - **Company**: Oric Pharmaceuticals (ORIC) - **Focus**: Development of ORIC-944, a potential best-in-class PRC2 inhibitor for metastatic castration-resistant prostate cancer (mCRPC) in combination with androgen receptor inhibitors (ARIs) like apalutamide and darolutamide [3][6][10] Key Points and Arguments Clinical Pipeline and Study Updates - ORIC is advancing two key programs with multiple data readouts expected in 2025 and early 2026, aiming for Phase 3 trials initiation in 2026 [6][10] - The ongoing Phase 1b study of ORIC-944 is focused on its combination with epalutamide and darolutamide in mCRPC patients [3][6] - Initial data indicates a favorable safety and activity profile for ORIC-944, with a focus on overcoming resistance in prostate cancer [8][10] Mechanism and Rationale - ORIC-944 is designed to address limitations of first-generation PRC2 inhibitors, showing improved potency and tolerability [7][13] - The combination of PRC2 inhibitors with ARIs is supported by biological rationale to delay or overcome resistance in prostate cancer [7][15] - Preclinical data shows ORIC-944 enhances AR signaling and luminal cell state markers, increasing sensitivity to AR inhibition [15][19] Efficacy and Safety Data - In the study, 17 patients with mCRPC showed a 59% PSA50 response rate and a 24% PSA90 response rate, with responses confirmed one month later [29][30] - The safety profile of ORIC-944 was generally well tolerated, with most adverse events being grade one or two, primarily mild gastrointestinal issues [31][32] - The combination therapy demonstrated a wide therapeutic window, with doses as low as 400 mg showing efficacy [30][31] Market Opportunity - The global market for AR inhibitors reached approximately $11 billion, with significant potential for PRC2 inhibitors to enhance treatment durability and outcomes [38][42] - ORIC-944 targets an addressable market opportunity of over $7 billion annually in the U.S. for mCRPC patients treated with AR inhibitors [42] Expansion Opportunities - ORIC-944 may have potential applications in other cancers, including breast and colorectal cancers, due to shared reliance on PRC2 mechanisms [44][48] - Future studies will explore ORIC-944 in earlier stages of prostate cancer and in combination with other therapies [48] Additional Important Content - The company completed a $125 million PIPE financing, extending its cash runway into the second half of 2027 [50] - The competitive landscape includes comparisons with Pfizer's mebrametostat, with ORIC-944 showing promising early efficacy and safety data [85][88] - The decision on which AR inhibitor to combine with for Phase 3 trials will be based on overall data and strategic considerations [79][80] This summary encapsulates the critical insights from the conference call, highlighting the company's strategic direction, clinical advancements, and market potential for ORIC-944 in prostate cancer treatment.